Abstract
Cardiovascular disease is a major health problem in all over the world. The prevalence of type 2 diabetes mellitus has been rapidly increasing, together with the risk for cardiovascular events. Patients with diabetes, and/or with insulin resistance as well, have an impaired myocardial metabolism of glucose and free fatty acids (FFA) and accelerated and diffuse atherogenesis, with involvement of peripheral coronary segments. Significant metabolic alterations in diabetic patients are the decreased utilization of glucose and the increase in muscular and myocardial FFA uptake and oxidation, occurring as a consequence of the mismatch between blood supply and cardiac metabolic requirements. These metabolic changes are responsible both for the increased susceptibility of the diabetic heart to myocardial ischemia and for a greater decrease of myocardial performance for a given amount of ischemia, compared to non diabetic hearts. A therapeutic approach aimed at an improvement of cardiac metabolism, through manipulations of the utilization of metabolic substrates, may improve myocardial ischemia and left ventricular function. Modulation of myocardial FFA metabolism, in addition to optimal medical therapy, should be the key target for metabolic interventions in patients with coronary artery disease and diabetes. In diabetic patients the effects of modulation of FFA metabolism should be even greater than those observed in patients without diabetes.
Keywords: Diabetes, cardiac metabolism, metabolic therapy, coronary artery disease, heart failure
Current Pharmaceutical Design
Title: Optimization of Cardiac Metabolism in Diabetes Mellitus
Volume: 14 Issue: 25
Author(s): Cristiana Vitale and Peter Collins
Affiliation:
Keywords: Diabetes, cardiac metabolism, metabolic therapy, coronary artery disease, heart failure
Abstract: Cardiovascular disease is a major health problem in all over the world. The prevalence of type 2 diabetes mellitus has been rapidly increasing, together with the risk for cardiovascular events. Patients with diabetes, and/or with insulin resistance as well, have an impaired myocardial metabolism of glucose and free fatty acids (FFA) and accelerated and diffuse atherogenesis, with involvement of peripheral coronary segments. Significant metabolic alterations in diabetic patients are the decreased utilization of glucose and the increase in muscular and myocardial FFA uptake and oxidation, occurring as a consequence of the mismatch between blood supply and cardiac metabolic requirements. These metabolic changes are responsible both for the increased susceptibility of the diabetic heart to myocardial ischemia and for a greater decrease of myocardial performance for a given amount of ischemia, compared to non diabetic hearts. A therapeutic approach aimed at an improvement of cardiac metabolism, through manipulations of the utilization of metabolic substrates, may improve myocardial ischemia and left ventricular function. Modulation of myocardial FFA metabolism, in addition to optimal medical therapy, should be the key target for metabolic interventions in patients with coronary artery disease and diabetes. In diabetic patients the effects of modulation of FFA metabolism should be even greater than those observed in patients without diabetes.
Export Options
About this article
Cite this article as:
Vitale Cristiana and Collins Peter, Optimization of Cardiac Metabolism in Diabetes Mellitus, Current Pharmaceutical Design 2008; 14 (25) . https://dx.doi.org/10.2174/138161208786071281
DOI https://dx.doi.org/10.2174/138161208786071281 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Carnosine Plus Vitamin E and Betaine Treatments on Oxidative Stress in Some Tissues of Aged Rats
Current Aging Science Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
Current Vascular Pharmacology Non-ACE Pathway-induced Angiotensin II Production
Current Pharmaceutical Design Biological Consequences of Dysfunctional HDL
Current Medicinal Chemistry Cell Therapy for Myocardial Regeneration
Current Molecular Medicine Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Erythropoietin Treatment in Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Drug Delivery Conduction Disorders in the Setting of Acute STEMI
Current Cardiology Reviews The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Pathophysiology of Patent Ductus Arteriosus in the Preterm Infant
Current Pediatric Reviews Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Societal and Cultural Attitudes to Gout: An Important Consideration in the Successful Management of Gout among Maori in Aotearoa New Zealand
Current Rheumatology Reviews Impact of Prone Position on Myocardial Perfusion SPECT Interpretation in Women with Suspected Coronary Disease
Current Medical Imaging Collagen Receptors as Potential Targets for Novel Anti-Platelet Agents
Current Pharmaceutical Design Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Medicinal Chemistry Cytochrome P450 in Neurological Disease
Current Drug Metabolism